Elizabeth Every - Vanda Pharmaceuticals Head Affairs
| VNDA Stock | USD 5.19 0.21 4.22% |
Insider
Elizabeth Every is Head Affairs of Vanda Pharmaceuticals
| Address | 2200 Pennsylvania Avenue NW, Washington, DC, United States, 20037 |
| Phone | 202 734 3400 |
| Web | https://www.vandapharma.com |
Vanda Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0364) % which means that it has lost $0.0364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0302) %, meaning that it created substantial loss on money invested by shareholders. Vanda Pharmaceuticals' management efficiency ratios could be used to measure how well Vanda Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Vanda Pharmaceuticals' Return On Tangible Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0, whereas Return On Capital Employed is forecasted to decline to (0.03). At present, Vanda Pharmaceuticals' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 226.3 M, whereas Other Current Assets are forecasted to decline to about 7.5 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Michelle Zhang | Ikena Oncology | N/A | |
| MBA MD | Ikena Oncology | 59 | |
| Lori CPA | Lumos Pharma | 40 | |
| Bradley JD | Lumos Pharma | 45 | |
| Hing Wong | HCW Biologics | 70 | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| Petpiboon Prasit | Tempest Therapeutics | N/A | |
| Lisa Miller | Lumos Pharma | N/A | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Jeffrey Ecsedy | Ikena Oncology | 54 | |
| Jennifer Schroeder | Ikena Oncology | N/A | |
| Richard Hawkins | Lumos Pharma | 75 | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| Jeff York | Seres Therapeutics | N/A | |
| MD BA | Lumos Pharma | 69 | |
| Carl Langren | Lumos Pharma | 69 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| Dr Dubensky | Tempest Therapeutics | 66 | |
| David MBA | Seres Therapeutics | 63 | |
Management Performance
| Return On Equity | -0.0302 | ||||
| Return On Asset | -0.0364 |
Vanda Pharmaceuticals Leadership Team
Elected by the shareholders, the Vanda Pharmaceuticals' board of directors comprises two types of representatives: Vanda Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vanda. The board's role is to monitor Vanda Pharmaceuticals' management team and ensure that shareholders' interests are well served. Vanda Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vanda Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Scott Howell, Chief Officer | ||
| Mihael MD, President, Founder | ||
| Kevin Moran, CFO VP | ||
| Elizabeth Every, Head Affairs | ||
| Joakim Wijkstrom, Chief Marketing Officer | ||
| Timothy Williams, Senior Vice President General Counsel, Secretary | ||
| Gunther Birznieks, Senior Vice President - Business Development | ||
| Timothy JD, General VP |
Vanda Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vanda Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0302 | ||||
| Return On Asset | -0.0364 | ||||
| Profit Margin | (0.09) % | ||||
| Operating Margin | (0.23) % | ||||
| Current Valuation | (77.95 M) | ||||
| Shares Outstanding | 58.31 M | ||||
| Shares Owned By Insiders | 3.15 % | ||||
| Shares Owned By Institutions | 76.98 % | ||||
| Number Of Shares Shorted | 3.22 M | ||||
| Price To Earning | 24.83 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Vanda Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vanda Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vanda Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vanda Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vanda Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vanda Pharmaceuticals. If investors know Vanda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vanda Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share (0.19) | Revenue Per Share 3.293 | Quarterly Revenue Growth 0.228 | Return On Assets (0.04) |
The market value of Vanda Pharmaceuticals is measured differently than its book value, which is the value of Vanda that is recorded on the company's balance sheet. Investors also form their own opinion of Vanda Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vanda Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vanda Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vanda Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vanda Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vanda Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vanda Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.